Abstract 4328
Background
The treatment of cancer has improved and many of the patients’ will return to work. Cancer treatments can have significant impact on work- and functional abilities creating challenges for return to work. Occupational health care services have an important role in supporting patients’ Return-to-Work-process. The purpose of the study was to a) explore cancer patients experiences on support received from occupational health services and b) explore how the services need to be developed.
Methods
Qualitative approach with thematic interview as data collection method was used to explore breast cancer patientś experiences (N = 8). The data was analysed by using thematic content analysis. Five of the cancer patients interviewed had already returned to work after cancer treatments and three were returning work in short period of time.
Results
The main challenges cancer patients confronted formed four categories; factors related to work, workplace, cancer and treatment types and to individual factors. The experienced support by occupational health services varied. The requirement to assess ability to work in the time of 90 sickness days was filled and planning the return-to-work in collaboration between occupational health care, cancer patient and employer occurred in most cases. However, otherwise, the role was passive and patients wished to have more contact with professionals working in the occupational health services.
Conclusions
Previous research highlights the need of collaboration between cancer patients and occupational health care services. Based on the study results, this collaboration needs to be enhanced. Occupational health care providers need to co-ordinate more actively the return-to-work -processes even the special health care is responsible for cancer treatments. From individual perspective, information, psychosocial support and regular evaluation of ability to work are forms of services cancer patient need from the occupational services for successful Return-to-Work. Results of this study can be used to developing occupational health services in national and international context.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Turku University of Applied Sciences.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4543 - Long-term real-world (RW) outcomes in patients with advanced melanoma (MEL) treated with ipilimumab (IPI) and non-IPI therapies: IMAGE study
Presenter: Stéphane Dalle
Session: Poster Display session 3
Resources:
Abstract
4523 - Prognostic Factors for efficacy of Ipilimumab used after AntiPD1 and/or BRAF+MEK inhibitors in Melanoma Patients: an Italian Melanoma Intergroup study
Presenter: Riccardo Marconcini
Session: Poster Display session 3
Resources:
Abstract
3632 - Rechallenge with combination ipilimumab and anti-PD-1 (IPI+PD1) in metastatic melanoma after acquired resistance to IPI+PD1 immunotherapy
Presenter: Adriana Hepner
Session: Poster Display session 3
Resources:
Abstract
3732 - Clinicopathologic characteristics of immune colitis in melanoma patients treated with combination ipilimumab and anti-PD1 (IPI+PD1) and PD1 monotherapy.
Presenter: Kazi Nahar
Session: Poster Display session 3
Resources:
Abstract
5005 - Real-world outcomes of ipilimumab plus nivolumab for advanced melanoma in the Netherlands
Presenter: Michiel van Zeijl
Session: Poster Display session 3
Resources:
Abstract
5524 - Utilization of Real-World Data to Assess the Effectiveness of Immune Checkpoint Inhibitors (ICIs) in Elderly Patients with Metastatic Melanoma
Presenter: D Scott Ernst
Session: Poster Display session 3
Resources:
Abstract
5884 - Tumor mutational burden and response to PD-1 inhibitors: an analysis of 89 cases of metastatic melanoma.
Presenter: Léa Dousset
Session: Poster Display session 3
Resources:
Abstract
3120 - Increase in S100B and LDH as early outcome predictors for non-responsiveness to anti-PD-1 monotherapy in advanced melanoma.
Presenter: Elisa Rozeman
Session: Poster Display session 3
Resources:
Abstract
2157 - Immune status defined by molecular information layers predicts response to pembrolizumab treatment in advanced melanoma
Presenter: Guillermo Prado-Vázquez
Session: Poster Display session 3
Resources:
Abstract
2553 - Interim analysis of a phase Ib study of cobimetinib plus atezolizumab in patients with advanced BRAFV600 wild type melanoma progressing on prior anti-PD-L1 therapy
Presenter: Shahneen Sandhu
Session: Poster Display session 3
Resources:
Abstract